Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics …

SOUTH SAN FRANCISCO, Calif., March 31, 2016 — Origent Data Sciences, Inc. (Origent) and Cytokinetics, Inc. (Nasdaq:CYTK) today announced a research collaboration to refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics’ clinical trials of tirasemtiv. Funded by Origent’s receipt of a grant from The ALS Association, this joint research program will enable the first prospective validation of the predictive model in a clinical trial setting. Previously, the Origent models predicting both function and survival of ALS patients have been validated using internal and retrospective external datasets. ALS disease progression is extremely heterogeneous among patients.  While the average life expectancy of a patient living with ALS is 3-5 years after diagnosis, many patients survive only a few months, while…


Link to Full Article: Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics …